WuXi AppTec's CRDMO model integrates drug discovery, development, testing, and manufacturing within one platform. By connecting capabilities across the drug development lifecycle, WuXi AppTec helps customers improve efficiency and accelerate new medicines to patients globally.

CRDMO: An Integrated Model to Accelerate Life-sciences Innovation

A CRDMO, or Contract Research, Development, and Manufacturing Organization, is an integrated biopharmaceutical partnership model that connects drug discovery, development, testing, and manufacturing within one coordinated framework. It brings together capabilities commonly associated with CRO, CDMO, and CMO services, including process development, analytical testing, Investigational New Drug (IND)-enabling services, formulation, and commercial manufacturing.

CRDMO.jpg

For patients waiting for new treatments, better coordination across these stages can help address one of drug development's persistent challenges: transforming promising science efficiently into tangible solutions.

For global innovators, the value of a CRDMO lies in continuity. Drug development is full of handoffs: from discovery to development, from development to manufacturing, from one site to another, and from one technical team to the next. Each transition can introduce delays, knowledge gaps, quality risks, or duplicated work.

An integrated CRDMO reduces these handoffs by keeping more work within one coordinated platform or a single site. This shortens timelines, improves technical alignment, and creates a clearer path from early development to clinical and commercial supply.

In today's drug development landscape, the CRDMO model is becoming more relevant as pipelines increasingly include sophisticated modalities that require innovative delivery technologies and combination approaches. These programs often require specialized expertise, new analytical assays, and early consideration of manufacturability. The CRDMO model is not simply an outsourcing solution. It is a partnership model built around continuity, technical depth, and execution. 

WuXi AppTec supports partners across more than 30 countries through operations spanning Asia, Europe, and North America. By integrating capabilities across research, development, testing, and manufacturing, WuXi AppTec collaborates with global innovators to advance promising science toward patients, guided by its vision that “every drug can be made and every disease can be treated.”

How WuXi Chemistry, WuXi Biology, and WuXi Testing Support the CRDMO Model

WuXi Chemistry provides integrated CRDMO services spanning drug discovery, development, scale-up, and commercial manufacturing. Its capabilities support synthetic molecular modalities across different development stages and scales, including small molecules, oligonucleotides, peptides, and complex conjugates.

By connecting chemistry research with downstream development and manufacturing, WuXi Chemistry supports continuity as drug candidates advance from early discovery toward clinical and commercial stages.

WuXi Chemistry: From Drug Discovery to Commercial Manufacturing

Drawing upon the early-stage drug discovery foundation, the CRDMO model also gains early insights into industry development opportunities, allowing us to plan capacity construction in advance to meet the evolving needs from global innovators.

Our combined development and manufacturing (D+M) services further empower early-stage innovators with comprehensive infrastructure, expertise, and technology needed to advance their pipeline at scale. With rapidly expanding capacity – spanning manufacturing of API, small molecules, peptides, oligonucleotides, and more - we are always ready to deliver when the demand for large-scale production rises.

Built on this foundation, WuXi AppTec's CRDMO model acts as a catalyst for healthcare innovation, seamlessly managing every stage from drug discovery to delivery. From small molecules, to emerging modalities, we are able to support all those transformative medicines that hold the promise to improve lives. Across oncology, immunology, neurological disorders, rare diseases, and many others, our efficiency translates directly to patients - faster access, more affordable treatments, and greater hope.

We're proud to work alongside our global partners to achieve the shared vision to build a future where "every drug can be made and every disease can be treated."

WuXi Biology: From Target Discovery to PCC

WuXi Biology provides a comprehensive spectrum of biology services and solutions, supporting stand-alone and integrated drug discovery projects. Its capabilities span target discovery, hit finding, lead optimization, candidate selection, and beyond, backed by established technology platforms and disease pharmacology expertise.

Within the CRDMO model, biology insights inform chemistry and program decisions across discovery and development, linking early science to downstream progression.

WuXi Testing: Integrated Testing Across Discovery and Development

WuXi Testing provides integrated testing capabilities across the discovery and development lifecycle. Its services support the evaluation of drug candidates as they progress from early research through preclinical and clinical development.

Within the CRDMO framework, WuXi Testing connects testing activities with discovery and development programs, helping generate the data needed to support candidate progression and the development of innovative medicines.

CRDMO in Action: How Integration Supports Drug Development

Integrated CRDMO programs accelerate drug development by connecting discovery, drug metabolism and pharmacokinetics (DMPK); toxicology, analytical development; chemistry, manufacturing, and controls (CMC); formulation; and manufacturing within one coordinated framework. 

The following case studies illustrate how the CRDMO model supports measurable outcomes across different therapeutic modalities.

Targeted Protein Degrader: From Development Challenges to IND-Enabling Materials in 12 Months

Targeted protein degraders selectively remove disease-causing proteins rather than simply inhibit them, offering a potential way to address historically difficult-to-drug targets. Their structural complexity, however, can create challenges across synthesis, formulation, analytical development, and manufacturing.

In one targeted protein degrader program, WuXi AppTec supported development across these areas, shortening the synthetic route from 24 steps to 16 and improving oral bioavailability by approximately 30-fold. The program delivered IND-enabling materials and clinical trial formulations within 12 months, about two months ahead of the original schedule.

To see how integrated CRDMO capabilities supported this targeted protein degrader from development challenges toward IND, read: CRDMO: From Concept to IND—How WuXi AppTec Supports Targeted Protein Degrader Development in 12 Months

Oligonucleotide-Lipid Conjugate: From PCC to IND Submission in Eight Months

Oligonucleotide-lipid conjugates combine the sequence-specific activity of oligonucleotide therapeutics with lipid components that can influence delivery and distribution. However, their combined molecular complexity can create challenges in synthesis, purification, analytical characterization, formulation, and scale-up.

In one small interfering RNA (siRNA)-lipid conjugate program, WuXi AppTec supported development from the preclinical candidate (PCC) stage toward IND submission by advancing lipid synthesis, oligonucleotide production, process development, analytics, formulation, and manufacturing in parallel. The optimized process achieved up to 95% homogeneous conversion, improved crude purity by approximately 20%, maintained final API endotoxin below 0.05 EU/mg, and completed the required CMC activities within eight months.

To see how integrated CRDMO capabilities helped accelerate oligonucleotide-lipid conjugate development toward IND submission, read: Conquering Oligonucleotide-Lipid Conjugate Process Challenges: How WuXi AppTec Accelerates Client Timelines

Complex Stapled Peptide: Phase 2 Clinical Trial Material Released in 11 Months

Stapled peptides are engineered to improve peptide stability and maintain biologically active conformations, making them a promising modality for targeting protein–protein interactions that can be difficult to address with conventional small molecules. Their structural complexity, however, can create significant challenges in API development, purification, analytical characterization, formulation, and manufacturing.

In one complex triple-stapled peptide program, WuXi AppTec advanced analytical method development in parallel with API production under Good Manufacturing Practice (GMP) requirements, while process optimization reduced residual ruthenium by approximately 75-fold from crude material to final API. Formulation development also produced a stable injectable solution at a concentration above 100 mg/mL, and the program progressed from project onboarding to Phase 2 clinical trial material release within 11 months.

To see how integrated development and manufacturing supported a complex peptide program from API development through clinical supply, read: Stapled Peptide Manufacturing: How WuXi AppTec's CRDMO Platform Helps Advance Complex Peptides to Clinical Supply

Radionuclide Drug Conjugate: Improving Development Speed, Purity, and Yield

A cyclic peptide-based radionuclide drug conjugate (RDC) program required rapid peptide optimization alongside process and analytical development. WuXi TIDES, WuXi AppTec's peptide and oligionucleotide platform, delivered more than 200 peptide variants at greater than 95% purity within four months. Working with WuXi Testing, the program further optimized molecular properties and evaluated lead compounds through in vitro and in vivo studies, ultimately supporting the client's nomination of a preclinical candidate.

As the RDC program advanced, process optimization reduced both synthesis cycle time and material consumption by approximately 30%. Improvements in impurity control and purification increased crude purity to 99% and raised overall yield from 29% to 44%, demonstrating how coordinated discovery, analytical, and process development can support RDC development from candidate optimization toward scalable manufacturing.

To learn how integrated CRDMO capabilities can address chemistry, purification, analytics, and manufacturing challenges in radionuclide drug conjugate development, read: Overcoming Challenges in Developing RDCs: WuXi AppTec's CRDMO Model

IND-Enabling Development: Coordinating DMPK, Toxicology, and Formulation

For a rare-disease program with limited regulatory precedent, IND preparation required coordinated assessment across DMPK, formulation, and toxicology. Cross-functional teams established an evaluation strategy and completed the required evaluation framework together with the full set of Good Laboratory Practice (GLP)-compliant toxicology studies in fewer than three months.

The coordinated approach supported the program's planned IND submission while demonstrating how DMPK, safety assessment, formulation, and regulatory preparation can be connected within an integrated development model. 

To see how integrated DMPK, toxicology, formulation, and other IND-enabling capabilities can support programs from discovery toward IND submission, read: How WuXi AppTec's Integrated CRDMO Model Supports Biotechnology Companies from Discovery to IND

These programs show how CRDMO integration can address different development bottlenecks. Rather than applying the same solution to every molecule, the model connects the scientific and operational capabilities needed for each program as it progresses.

Frequently Asked Questions About the CRDMO Model

WuXi Chemistry
WuXi Chemistry
Provides CRDMO services for new drug development from discovery to commercial, meeting any material requirement at any scale and covering all categories for all synthetic molecular modalities, including small molecules, oligonucleotides, peptides and complex conjugates
WuXi Biology
WuXi Biology
A full spectrum of biology services and solutions, that support stand-alone and integrated projects, from target discovery to candidate selection and into the clinic
WuXi Testing
WuXi Testing
An integrated testing platform across the full life cycle of discovery and development to help customers deliver innovative medicines to patients.